Antibody-drug conjugates (ADCs) are created by linking highly specific monoclonal antibodies (the "antibody" component) with potent small molecule toxic drugs (commonly referred to as "drug," "payload," or "warhead") using linkers.
In comparison to using antibodies or small molecule drugs individually, ADC drugs provide a unique combination of small molecule and antibody drug advantages. Presently, there are fifteen (15) ADC drugs approved for commercial use worldwide.
Abosyn has developed more than 100 distinctive products, including Exatecan and their derivatives, linkers, and payload-linker complexes.
0
